Axa
CTIC

Axa’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Axa’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,100
Closed -$103K – 1213
2022
Q4 		$103K Sell
17,100
-16,000
-48% -$87.3K ﹤0.01% 1112
2022
Q3 		$193K Buy
33,100
+17,100
+107% +$107K ﹤0.01% 1096
2022
Q2 		$95.5K Buy
+16,000
New +$81.9K ﹤0.01% 1098
2019
Q1 		– Sell
-27,400
Closed -$20K – 1442
2018
Q4 		$20K Sell
27,400
-34,600
-56% -$56.8K ﹤0.01% 1292
2018
Q3 		$134K Sell
62,000
-43,500
-41% -$108K ﹤0.01% 1313
2018
Q2 		$525K Buy
105,500
+87,000
+470% +$381K ﹤0.01% 1122
2018
Q1 		$72K Buy
+18,500
New +$65.1K ﹤0.01% 1356

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Axa's CTIC Position: Q1 2023 in Review

Axa sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 17,100 shares — an estimated $103K sold.

Axa first reported a position in CTIC in Q1 2018 and held it in 7 quarters. The position peaked at $525K in Q2 2018. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • Axa reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • Axa sold 17,100 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $103K.
  • Axa first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2018 and held it in 7 quarters.
  • Axa's CTI BioPharma Corp. (DE) Common Stock position peaked at $525K in Q2 2018.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.